Home › Merck to Present New Data on VICTRELIS (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting
 

Keywords :   


Merck to Present New Data on VICTRELIS (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting

2013-04-08 16:37:00| Merck.com - Product News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Mercks investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. The meeting will take place in Amsterdam from April 24-28, 2013. Language:  English Contact HTML:  MerckMedia:Caroline Lappetito, 267-305-7369Sarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: data international present meeting

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.10Eastern North Pacific Tropical Weather Outlook
04.10Tropical Storm Leslie Graphics
04.10Hurricane Kirk Graphics
04.10Tropical Storm Leslie Forecast Discussion Number 7
04.10Tropical Storm Leslie Wind Speed Probabilities Number 7
04.10Tropical Storm Leslie Public Advisory Number 7
04.10Summary for Tropical Storm Leslie (AT3/AL132024)
04.10Tropical Storm Leslie Forecast Advisory Number 7
More »